AHA 2008: Blood test identifies heart failure patients in ER
This article was originally published in Clinica
A new blood test identifies the sickest heart failure patients better than current tests used in US emergency departments, a trial has shown. Presented at the AHA meeting, the BACH study followed 1,641 patients who experienced difficulty breathing upon arrival at the emergency department. The researchers found that the MR-proADM test, developed by German firm Brahms, was prognostically accurate 73.1% of the time, making it superior to the commonly-used B-natriuretic peptide (BNP) test (60.6%) and the NTproBNP test (63%). The new test also predicted the 90-day mortality of these patients. The MR-proADM test indirectly measures adrenomedullin, which affects blood vessel dilation and is implicated in many cardiac and infectious diseases. It was CE marked for sale in Europe in October; US approval applications will be submitted in early 2009.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.